China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Other Non-Current Liabilities of $16563.0 for Q1 2026, down 69.26% year-over-year from $53885.0 in Q1 2025, and up 2.3% quarter-over-quarter from $16191.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $16563.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 69.26% year-over-year to $16563.0; the TTM figure through Mar 2026 stood at $16563.0 (down 69.26% YoY), while the FY2026 annual figure was $16563.0, down 69.26% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $16563.0, up from $16191.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $219740.0 in Q3 2024, with the low at $16191.0 in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $111951.0 (2023), against an average of $112237.1.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 90.77% in 2024, then plunged 92.63% in 2025.
- China SXT Pharmaceuticals' Other Non-Current Liabilities stood at $109411.0 in 2022, then jumped by 33.49% to $146049.0 in 2023, then surged by 50.46% to $219740.0 in 2024, then slumped by 92.63% to $16191.0 in 2025, then advanced by 2.3% to $16563.0 in 2026.
- Business Quant data shows SXTC's Other Non-Current Liabilities at $16563.0 in Q1 2026, $16191.0 in Q3 2025, and $53885.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | China SXT Pharmaceuticals | 32,029.07 | -28.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,563.00 |
| Sep 30, 2025 | 16,191.00 |
| Mar 31, 2025 | 53,885.00 |
| Sep 30, 2024 | 219,740.00 |
| Mar 31, 2024 | 213,571.00 |
| Sep 30, 2023 | 146,049.00 |
| Mar 31, 2023 | 111,951.00 |
| Sep 30, 2022 | 109,411.00 |
| Mar 31, 2022 | 122,773.00 |
| Sep 30, 2021 | 480,227.00 |
| Mar 31, 2021 | 472,282.00 |
| Sep 30, 2020 | 104,814.00 |
| Mar 31, 2020 | 113,611.00 |
| Sep 30, 2019 | 73,533.00 |
| Mar 31, 2019 | 78,317.00 |